SwePub
Sök i LIBRIS databas

  Extended search

L773:1941 837X
 

Search: L773:1941 837X > (2015-2019) > Cost-effectiveness ...

  • Hofmarcher, ThomasLund University,Lunds universitet,Nationalekonomiska institutionen,Ekonomihögskolan,Department of Economics,Lund University School of Economics and Management, LUSEM,IHE – The Swedish Institute for Health Economics (author)

Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015-03-31
  • Informa Healthcare,2015
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:85b25ab3-8cad-4ead-ab9b-344e11170173
  • https://lup.lub.lu.se/record/5261683URI
  • https://doi.org/10.3111/13696998.2015.1029491DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • OBJECTIVE: Iron deficiency is a common but treatable comorbidity in chronic heart failure (CHF) that is associated with impaired health-related quality-of-life (HRQoL). This study evaluates the cost-effectiveness of the intravenous iron preparation ferric carboxymaltose (FCM) for the treatment of iron deficiency in CHF from a Swedish healthcare perspective. METHODS: A cost-effectiveness analysis with a time horizon of 24 weeks was performed to compare FCM treatment with placebo. Data on health outcomes and medical resource use were mainly taken from the FAIR-HF trial and combined with Swedish cost data. An incremental cost-effectiveness ratio (ICER) was calculated as well as the change in per-patient costs for primary care and hospital care. RESULTS: In the FCM group compared with placebo, quality-adjusted life years (QALYs) are higher (difference = 0.037 QALYs), but so are per-patient costs [(difference = SEK 2789 (€303)]. Primary care and hospital care equally share the additional costs, but within hospitals there is a major shift of costs from inpatient care to outpatient care. The ICER is SEK 75,389 (€8194) per QALY. The robustness of the result is supported by sensitivity analyses. CONCLUSIONS: Treatment of iron deficiency in CHF with FCM compared with placebo is estimated to be cost-effective. The ICER in the base case scenario is twice as high as previously thought, but noticeably below SEK 500,000 (€54,300) per QALY, an informal average reference value used by the Swedish Dental and Pharmaceutical Benefits Agency. Increased HRQoL and fewer hospitalizations are the key drivers of this result.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Borg, SixtenLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,Evidera Ltd(Swepub:lu)med-sxb (author)
  • Nationalekonomiska institutionenEkonomihögskolan (creator_code:org_t)

Related titles

  • In:Journal of Medical Economics: Informa Healthcare18:7, s. 492-5011941-837X1369-6998

Internet link

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Hofmarcher, Thom ...
Borg, Sixten
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Health Sciences
and Health Care Serv ...
Articles in the publication
Journal of Medic ...
By the university
Lund University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view